PMID- 12167392
OWN - NLM
STAT- MEDLINE
DCOM- 20021029
LR  - 20190513
IS  - 1388-9842 (Print)
IS  - 1388-9842 (Linking)
VI  - 4
IP  - 4
DP  - 2002 Aug
TI  - Torasemide in chronic heart failure: results of the TORIC study.
PG  - 507-13
AB  - BACKGROUND: Diuretics such as torasemide are commonly used to treat chronic heart 
      failure (CHF). AIMS: The objective of the TOrasemide In Congestive Heart Failure 
      (TORIC) Study was to investigate the safety, tolerability and efficacy of 
      torasemide in CHF patients compared to furosemide or other diuretics in an 
      open-label, non-randomised, post-marketing surveillance trial. METHODS: The 
      present analysis shows the findings of 1377 patients with New York Heart 
      Association (NYHA) class II-III CHF who received diuretic therapy with torasemide 
      10 mg/day orally (n=778) vs. patients who received furosemide 40 mg/day orally 
      (n=527) or other diuretics (n=72) on top of their existing standard CHF therapy 
      for 12 months. Besides safety and tolerability, efficacy was assessed by 
      documentation of mortality, morbidity, functional class and serum potassium 
      levels every 3 months. RESULTS: TORIC confirmed the safety and tolerability of 
      torasemide in CHF patients. Mortality was significantly lower in the torasemide 
      (n=17, 2.2%) than in the furosemide/other diuretics group (n=27, 4.5%) (P<0.05). 
      Functional improvement as assessed by NYHA class was observed in more patients 
      who received furosemide torasemide (n=356, 45.8%) than those who received 
      furosemide/other diuretics (n=223, 37.2%) (P=0.00017). At the end of the study 
      abnormally low serum potassium levels were observed in fewer torasemide (n=95, 
      12.9%) than furosemide/other diuretics patients (n=102, 17.9%) (P=0.013). 
      CONCLUSION: Torasemide is safe and well tolerated in CHF patients. Although not 
      designed as a mortality study, TORIC suggests a lower mortality amongst CHF 
      patients treated with torasemide compared to furosemide/other diuretics. A 
      functional improvement and a lower incidence of abnormal serum potassium levels 
      were also observed in patients receiving torasemide as compared to those 
      receiving furosemide/other diuretics.
FAU - Cosin, Juan
AU  - Cosin J
AD  - Cardiocirculatory Research Unit, Research Center, University Hospital La Fe, 
      Valencia, Spain.
FAU - Diez, Javier
AU  - Diez J
CN  - TORIC investigators
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - England
TA  - Eur J Heart Fail
JT  - European journal of heart failure
JID - 100887595
RN  - 0 (Diuretics)
RN  - 0 (Sulfonamides)
RN  - 7LXU5N7ZO5 (Furosemide)
RN  - RWP5GA015D (Potassium)
RN  - W31X2H97FB (Torsemide)
SB  - IM
EIN - Eur J Heart Fail 2002 Oct;4(5):667
MH  - Aged
MH  - Chronic Disease
MH  - Diuretics/adverse effects/*therapeutic use
MH  - Female
MH  - Furosemide/adverse effects/therapeutic use
MH  - Heart Failure/*drug therapy/mortality/physiopathology
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Potassium/blood
MH  - Product Surveillance, Postmarketing
MH  - Stroke Volume/drug effects/physiology
MH  - Sulfonamides/adverse effects/*therapeutic use
MH  - Survival Rate
MH  - Torsemide
MH  - Treatment Outcome
MH  - Ventricular Function, Left/drug effects/physiology
EDAT- 2002/08/09 10:00
MHDA- 2002/10/31 04:00
CRDT- 2002/08/09 10:00
PHST- 2002/08/09 10:00 [pubmed]
PHST- 2002/10/31 04:00 [medline]
PHST- 2002/08/09 10:00 [entrez]
AID - S1388984202001228 [pii]
AID - 10.1016/s1388-9842(02)00122-8 [doi]
PST - ppublish
SO  - Eur J Heart Fail. 2002 Aug;4(4):507-13. doi: 10.1016/s1388-9842(02)00122-8.